SCHEMBL21940800

SCHEMBL21940800

Cc1cc(C#N)nnc1N1C[C@@H](C)O[C@H](C)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.44
ALDH1A1 P00352 12/20 0.42
GAA P10253 4/20 0.42
LMNA P02545 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
KMT2A Q03164 6/20 0.42
MEN1 O00255 5/20 0.42
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HSD17B10 Q99714 5/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
TSHR P16473 4/20 0.39
MAPT P10636 4/20 0.39
CASP1 P29466 2/20 0.39
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21940293 1.00 KDM4E (0.44) KDM4EALDH1A1GAALMNAL3MBTL1
SCHEMBL21940582 1.00 KDM4E (0.44) KDM4EALDH1A1GAALMNAL3MBTL1
SCHEMBL21940802 1.00 KDM4E (0.44) KDM4EALDH1A1GAALMNAL3MBTL1
SCHEMBL21940294 0.83 LRRK2 (0.44) KDM4EALDH1A1HSD17B10HPGD
SCHEMBL21940791 0.83 LRRK2 (0.44) KDM4EALDH1A1HSD17B10HPGD
SCHEMBL21940290 0.75 KDM4E (0.32) KDM4EALDH1A1LMNAKMT2AMEN1
SCHEMBL21940286 0.73 ALDH1A1 (0.42) KDM4EALDH1A1GAALMNAL3MBTL1
SCHEMBL21940787 0.73 CHRM4 (0.35) KDM4EALDH1A1HSD17B10TSHRHPGD
SCHEMBL15831800 0.71 HRH4 (0.66) KDM4EALDH1A1GAALMNAL3MBTL1
SCHEMBL20606768 0.69 LRRK2 (0.40) KDM4EALDH1A1HSD17B10TSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3423445-B1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS GALAPAGOS NV (BE) 2020-04-01 EP disclosed